Published in J Clin Microbiol on May 16, 2012
Mechanisms of vancomycin resistance in Staphylococcus aureus. J Clin Invest (2014) 1.15
Antimicrobial activity of ceftaroline tested against staphylococci with reduced susceptibility to linezolid, daptomycin, or vancomycin from U.S. hospitals, 2008 to 2011. Antimicrob Agents Chemother (2013) 0.98
Variability of antibiotic susceptibility and toxin production of Staphylococcus aureus strains isolated from skin, soft tissue, and bone related infections. BMC Microbiol (2013) 0.84
Impact of the functional status of saeRS on in vivo phenotypes of Staphylococcus aureus sarA mutants. Mol Microbiol (2014) 0.83
Clinical, microbiological, and genetic characteristics of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia in a teaching hospital. Microb Drug Resist (2014) 0.79
Activity of Tedizolid in Methicillin-Resistant Staphylococcus aureus Experimental Foreign Body-Associated Osteomyelitis. Antimicrob Agents Chemother (2016) 0.78
Prevalence of methicillin-resistant Staphylococcus aureus (MRSA) infection and the molecular characteristics of MRSA bacteraemia over a two-year period in a tertiary teaching hospital in Malaysia. BMC Infect Dis (2017) 0.78
Activity of Tedizolid in Methicillin-Resistant Staphylococcus epidermidis Experimental Foreign Body-Associated Osteomyelitis. Antimicrob Agents Chemother (2016) 0.77
Phenotypic Characteristics of Vancomycin-Non-Susceptible Staphylococcus aureus. Jundishapur J Microbiol (2016) 0.76
Effects of aggregate and individual antibiotic exposure on vancomycin MICs for Staphylococcus aureus isolates recovered from pediatric patients. J Clin Microbiol (2013) 0.76
Methicillin-Resistant Staphylococcus aureus Grown on Vancomycin-Supplemented Screening Agar Displays Enhanced Biofilm Formation. Antimicrob Agents Chemother (2015) 0.75
Natural lipopeptide antibiotic tripropeptin C revitalizes and synergistically potentiates the activity of beta-lactams against methicillin-resistant Staphylococcus aureus. J Antibiot (Tokyo) (2015) 0.75
Screening for Intermediately Vancomycin-Susceptible and Vancomycin-Heteroresistant Staphylococcus aureus by Use of Vancomycin-Supplemented Brain Heart Infusion Agar Biplates: Defining Growth Interpretation Criteria Based on Gold Standard Confirmation. J Clin Microbiol (2015) 0.75
Community-associated methicillin-resistant Staphylococcus aureus infection: Literature review and clinical update. Can Fam Physician (2017) 0.75
Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet (1997) 18.24
Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis (2008) 8.58
Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol (2004) 6.65
A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J Antimicrob Chemother (2001) 5.83
Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect Dis (2001) 5.28
Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin. Antimicrob Agents Chemother (2002) 4.83
Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev (2010) 4.76
The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis (2012) 4.20
Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis (2004) 4.09
Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis (2004) 4.06
Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations. J Infect Dis (2011) 3.98
Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50. Antimicrob Agents Chemother (2000) 3.51
Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia. J Infect Dis (2009) 3.04
Reduced susceptibility to vancomycin influences pathogenicity in Staphylococcus aureus infection. J Infect Dis (2009) 2.72
Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother (2006) 2.43
Evolution of multidrug resistance during Staphylococcus aureus infection involves mutation of the essential two component regulator WalKR. PLoS Pathog (2011) 2.15
Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007). J Clin Microbiol (2008) 2.07
Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections. Int J Antimicrob Agents (2008) 2.03
Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years. J Clin Microbiol (2009) 2.00
Genomic analysis reveals a point mutation in the two-component sensor gene graS that leads to intermediate vancomycin resistance in clinical Staphylococcus aureus. Antimicrob Agents Chemother (2008) 1.89
Evaluation of a new Etest vancomycin-teicoplanin strip for detection of glycopeptide-intermediate Staphylococcus aureus (GISA), in particular, heterogeneous GISA. J Clin Microbiol (2008) 1.86
Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates. Antimicrob Agents Chemother (2010) 1.80
Vancomycin MICs for methicillin-resistant Staphylococcus aureus isolates differ based upon the susceptibility test method used. Antimicrob Agents Chemother (2008) 1.51
Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-susceptible MRSA. Antimicrob Agents Chemother (2009) 1.50
Vancomycin minimum inhibitory concentration and outcome in patients with Staphylococcus aureus bacteremia: pearl or pellet? J Infect Dis (2011) 1.41
Practical strategies for detecting and confirming vancomycin-intermediate Staphylococcus aureus: a tertiary-care hospital laboratory's experience. J Clin Microbiol (2001) 1.37
Resistance to teicoplanin developing during treatment of methicillin-resistant Staphylococcus aureus infection. J Antimicrob Chemother (2002) 1.21
Performance of various testing methodologies for detection of heteroresistant vancomycin-intermediate Staphylococcus aureus in bloodstream isolates. J Clin Microbiol (2011) 1.16
Predictors of high vancomycin MIC values among patients with methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother (2008) 1.08
Staphylococcus aureus isolates with reduced susceptibility to glycopeptides belong to accessory gene regulator group I or II. Antimicrob Agents Chemother (2004) 0.98
Peripheral intravenous catheter-associated Staphylococcus aureus bacteraemia: more than 5 years of prospective data from two tertiary health services. Med J Aust (2013) 4.93
Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev (2010) 4.76
Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis (2004) 4.09
Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis (2004) 4.06
Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations. J Infect Dis (2011) 3.98
Giant plasmid-encoded polyketide synthases produce the macrolide toxin of Mycobacterium ulcerans. Proc Natl Acad Sci U S A (2004) 3.52
Reductive evolution and niche adaptation inferred from the genome of Mycobacterium ulcerans, the causative agent of Buruli ulcer. Genome Res (2007) 3.45
Insights from the complete genome sequence of Mycobacterium marinum on the evolution of Mycobacterium tuberculosis. Genome Res (2008) 3.26
Ecology and transmission of Buruli ulcer disease: a systematic review. PLoS Negl Trop Dis (2010) 2.98
Development and application of two multiplex real-time PCR assays for the detection of Mycobacterium ulcerans in clinical and environmental samples. Appl Environ Microbiol (2007) 2.75
2009 H1N1 influenza A and pregnancy outcomes in Victoria, Australia. Clin Infect Dis (2010) 2.60
Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother (2006) 2.43
Mycobacterium ulcerans disease. Bull World Health Organ (2005) 2.30
Staphylococcus aureus bacteraemia: a major cause of mortality in Australia and New Zealand. Med J Aust (2009) 2.16
Methicillin-resistant Staphylococcus aureus in hospitals: time for a culture change. Med J Aust (2007) 2.06
Conundrums in community-acquired pneumonia. Med J Aust (2006) 2.04
Antimicrobial resistance: Not community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA)! A clinician's guide to community MRSA - its evolving antimicrobial resistance and implications for therapy. Clin Infect Dis (2011) 2.00
Genomic analysis reveals a point mutation in the two-component sensor gene graS that leads to intermediate vancomycin resistance in clinical Staphylococcus aureus. Antimicrob Agents Chemother (2008) 1.89
A major role for mammals in the ecology of Mycobacterium ulcerans. PLoS Negl Trop Dis (2010) 1.80
Serine/threonine phosphatase Stp1 contributes to reduced susceptibility to vancomycin and virulence in Staphylococcus aureus. J Infect Dis (2012) 1.78
Two novel point mutations in clinical Staphylococcus aureus reduce linezolid susceptibility and switch on the stringent response to promote persistent infection. PLoS Pathog (2010) 1.74
Outbreak investigation using high-throughput genome sequencing within a diagnostic microbiology laboratory. J Clin Microbiol (2013) 1.71
Oseltamivir resistance in adult oncology and hematology patients infected with pandemic (H1N1) 2009 virus, Australia. Emerg Infect Dis (2010) 1.70
Efficacy of soap and water and alcohol-based hand-rub preparations against live H1N1 influenza virus on the hands of human volunteers. Clin Infect Dis (2009) 1.67
In vitro pharmacodynamics of colistin against multidrug-resistant Klebsiella pneumoniae. J Antimicrob Chemother (2008) 1.66
First case of Mycobacterium ulcerans disease (Bairnsdale or Buruli ulcer) acquired in New South Wales. Med J Aust (2007) 1.56
Outcomes for Mycobacterium ulcerans infection with combined surgery and antibiotic therapy: findings from a south-eastern Australian case series. Med J Aust (2007) 1.56
Cytokine profiles of patients infected with Mycobacterium ulcerans and unaffected household contacts. Infect Immun (2002) 1.54
Risk factors for Mycobacterium ulcerans infection, southeastern Australia. Emerg Infect Dis (2007) 1.53
Different bacterial gene expression patterns and attenuated host immune responses are associated with the evolution of low-level vancomycin resistance during persistent methicillin-resistant Staphylococcus aureus bacteraemia. BMC Microbiol (2008) 1.46
Transfer of vancomycin resistance transposon Tn1549 from Clostridium symbiosum to Enterococcus spp. in the gut of gnotobiotic mice. Antimicrob Agents Chemother (2006) 1.43
Complete genome sequence of Staphylococcus aureus strain JKD6008, an ST239 clone of methicillin-resistant Staphylococcus aureus with intermediate-level vancomycin resistance. J Bacteriol (2010) 1.43
Vancomycin AUC/MIC ratio and 30-day mortality in patients with Staphylococcus aureus bacteremia. Antimicrob Agents Chemother (2013) 1.38
Genomic insights to control the emergence of vancomycin-resistant enterococci. MBio (2013) 1.37
A sustained hospital outbreak of vancomycin-resistant Enterococcus faecium bacteremia due to emergence of vanB E. faecium sequence type 203. J Infect Dis (2010) 1.27
Comparative analysis of the first complete Enterococcus faecium genome. J Bacteriol (2012) 1.27
Acquired T-helper 1 lymphocyte anergy following infection with Mycobacterium ulcerans. Clin Infect Dis (2003) 1.23
Evaluation of VNTR typing for the identification of Mycobacterium ulcerans in environmental samples from Victoria, Australia. FEMS Microbiol Lett (2008) 1.21
The dominant Australian community-acquired methicillin-resistant Staphylococcus aureus clone ST93-IV [2B] is highly virulent and genetically distinct. PLoS One (2011) 1.16
The interface between antibiotic resistance and virulence in Staphylococcus aureus and its impact upon clinical outcomes. Clin Infect Dis (2011) 1.16
Subtractive hybridization reveals a type I polyketide synthase locus specific to Mycobacterium ulcerans. J Bacteriol (2003) 1.15
Correlation between Buruli ulcer and vector-borne notifiable diseases, Victoria, Australia. Emerg Infect Dis (2009) 1.15
Acute, oedematous Mycobacterium ulcerans infection in a farmer from far north Queensland. Med J Aust (2002) 1.14
Risk factors for new detection of vancomycin-resistant enterococci in acute-care hospitals that employ strict infection control procedures. Antimicrob Agents Chemother (2003) 1.13
Outcomes from the first 2 years of the Australian National Hand Hygiene Initiative. Med J Aust (2011) 1.13
Epidemiology and management of Buruli ulcer. Expert Rev Anti Infect Ther (2014) 1.13
Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients. Antimicrob Agents Chemother (2006) 1.13
Severe complications of a "Brazilian" bikini wax. Clin Infect Dis (2007) 1.13
All-oral antibiotic treatment for buruli ulcer: a report of four patients. PLoS Negl Trop Dis (2010) 1.11
Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure. J Antimicrob Chemother (2011) 1.10
Mycobacterium ulcerans infection: factors influencing diagnostic delay. Med J Aust (2007) 1.09
Risk of Buruli ulcer and detection of Mycobacterium ulcerans in mosquitoes in southeastern Australia. PLoS Negl Trop Dis (2011) 1.09
Serological evaluation of Mycobacterium ulcerans antigens identified by comparative genomics. PLoS Negl Trop Dis (2010) 1.08
Spontaneous clearance of Mycobacterium ulcerans in a case of Buruli ulcer. PLoS Negl Trop Dis (2011) 1.08
Australia's influenza containment plan and the swine flu epidemic in Victoria. Med J Aust (2009) 1.08
Extensively resistant tuberculosis in the lands Down Under. Med J Aust (2011) 1.07
Climate and landscape factors associated with Buruli ulcer incidence in Victoria, Australia. PLoS One (2012) 1.06
Acquired bloodstream infection in the intensive care unit: incidence and attributable mortality. Crit Care (2011) 1.03
The RpoB H₄₈₁Y rifampicin resistance mutation and an active stringent response reduce virulence and increase resistance to innate immune responses in Staphylococcus aureus. J Infect Dis (2012) 1.02
The incubation period of Buruli ulcer (Mycobacterium ulcerans infection). PLoS Negl Trop Dis (2013) 1.01
Once bitten, twice shy: an unusual case report of a mycotic aortic aneurysm. ANZ J Surg (2005) 0.99
Inactivation of the indigenous methyltransferase RlmN in Staphylococcus aureus increases linezolid resistance. Antimicrob Agents Chemother (2011) 0.99
Complete genome sequence of Staphylococcus aureus strain JKD6159, a unique Australian clone of ST93-IV community methicillin-resistant Staphylococcus aureus. J Bacteriol (2010) 0.98
Comparative analysis of the complete genome of an epidemic hospital sequence type 203 clone of vancomycin-resistant Enterococcus faecium. BMC Genomics (2013) 0.98
An unusual presentation of herpes simplex virus encephalitis. Case Rep Med (2012) 0.97
Failure of vancomycin for treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis (2004) 0.96
Decreased vancomycin susceptibility in Staphylococcus aureus caused by IS256 tempering of WalKR expression. Antimicrob Agents Chemother (2013) 0.96
Mycolactone gene expression is controlled by strong SigA-like promoters with utility in studies of Mycobacterium ulcerans and buruli ulcer. PLoS Negl Trop Dis (2009) 0.95
The molecular epidemiology of the highly virulent ST93 Australian community Staphylococcus aureus strain. PLoS One (2012) 0.94
Complete Bypass of Restriction Systems for Major Staphylococcus aureus Lineages. MBio (2015) 0.94
Adaptive change inferred from genomic population analysis of the ST93 epidemic clone of community-associated methicillin-resistant Staphylococcus aureus. Genome Biol Evol (2014) 0.92
High-resolution melting genotyping of Enterococcus faecium based on multilocus sequence typing derived single nucleotide polymorphisms. PLoS One (2011) 0.92
Evaluation of the Xpert™ MRSA/SA Blood Culture assay for the detection of Staphylococcus aureus including strains with reduced vancomycin susceptibility from blood culture specimens. Diagn Microbiol Infect Dis (2011) 0.92
Molecular epidemiology of enterococcal bacteremia in Australia. J Clin Microbiol (2014) 0.90
Comparing the pneumonia severity index with CURB-65 in patients admitted with community acquired pneumonia. Scand J Infect Dis (2008) 0.89
Detection of enterohaemorrhagic Escherichia coli in patients attending hospital in Melbourne, Australia. Pathology (2004) 0.88
Treatment of Staphylococcus aureus infections: new issues, emerging therapies and future directions. Expert Opin Emerg Drugs (2007) 0.87
What's new in the treatment of serious MRSA infection? Curr Opin Infect Dis (2014) 0.87
Steroids control paradoxical worsening of Mycobacterium ulcerans infection following initiation of antibiotic therapy. Med J Aust (2013) 0.86
Treating Gram-positive infections: vancomycin update and the whys, wherefores and evidence base for continuous infusion of anti-Gram-positive antibiotics. Curr Opin Infect Dis (2009) 0.85
Human fasciolosis acquired in an Australian urban setting. Med J Aust (2003) 0.84
Granulomatous hepatitis: tuberculosis or not? Med J Aust (2008) 0.83
Long-term carriage of vancomycin-resistant enterococci in patients discharged from hospitals: a 12-year retrospective cohort study. J Clin Microbiol (2013) 0.83
New aspirations: the debate on aspiration pneumonia treatment guidelines. Med J Aust (2011) 0.81
Case-case-control study on factors associated with vanB vancomycin-resistant and vancomycin-susceptible enterococcal bacteraemia. BMC Infect Dis (2014) 0.81
Pooled human immunoglobulin therapy in critically Ill patients with pandemic 2009 influenza A(H1N1) pneumonitis and immunoglobulin G2 subclass (IgG2) deficiency. Clin Infect Dis (2010) 0.81
Mycobacterium ulcerans DNA not detected in faecal samples from Buruli ulcer patients: results of a pilot study. PLoS One (2011) 0.80
Can we readily identify patients who need antibiotics in a severe influenza pandemic? Med J Aust (2009) 0.80